{"id":"CHEMBL1064","canonicalSmiles":"CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21","inchiKey":"RYMZZMVNJRMUDD-HGQWONQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SIMVASTATIN","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Flolipid","Lacersa","Ranzolont","Simvador","Simvastatin","Zocor","Zocor heart-pro"],"synonyms":["C10AA01","MK-0733","MK-733","NSC-758706","Simvastatin","Simvastatin hydroxy acid","Synvinolin"],"crossReferences":{"DailyMed":["simvastatin"],"PubChem":["144204247","144210718","164339438","170464984","496592","50086525"],"TG-GATEs":["117"],"Wikipedia":["Simvastatin"],"drugbank":["DB00641"],"chEBI":["9150"]},"linkedTargets":{"rows":["ENSG00000113161"],"count":1},"linkedDiseases":{"rows":["Orphanet_818","EFO_0001361","EFO_0007486","EFO_0000275","EFO_0000401","EFO_0004698","EFO_1001951","EFO_0003914","HP_0100543","EFO_0008585","EFO_0002690","MONDO_0008903","EFO_0003884","EFO_1000652","EFO_0000400","EFO_0000407","MONDO_0002635","EFO_0002618","MONDO_0005149","HP_0012532","EFO_0004197","EFO_0000666","EFO_0000660","MONDO_0008315","EFO_0001663","EFO_0001422","EFO_1001231","EFO_0000574","MONDO_0004979","EFO_0007328","EFO_0001378","EFO_0000341","EFO_0005672","EFO_0003086","EFO_0007405","MONDO_0007254","Orphanet_586","EFO_0008568","MONDO_0001056","EFO_0000289","MONDO_0005180","EFO_0009854","EFO_0004319","Orphanet_648","EFO_0001645","EFO_0003929","EFO_0000319","EFO_0001073","EFO_0004911","EFO_0000537","EFO_0000195","EFO_0004268","MONDO_0001134","EFO_1001121","EFO_0000649","EFO_0000764","Orphanet_79211","EFO_0000702","MONDO_0043510","MONDO_0005148","EFO_0005411","EFO_0004265","EFO_0004264","MONDO_0002009","EFO_1000657","EFO_0005669","EFO_0000266","EFO_1001898","EFO_0004208","EFO_0008522","EFO_0009441","HP_0003124","HP_0001685","HP_0001919","MONDO_0008170","EFO_1001466","Orphanet_309005","HP_0100806","MP_0001845","MONDO_0100096","EFO_0004192","MONDO_0021187","EFO_0000731","EFO_0009878","MONDO_0005090","EFO_0006834","Orphanet_232","EFO_0001065","EFO_0000464","EFO_0003876","EFO_0000305","EFO_1002048","MONDO_0001187","EFO_0600064","EFO_0004211","EFO_1001480","MONDO_0005277","EFO_0000474","EFO_1001375","EFO_0003144","EFO_0000712","HP_0003119","EFO_1001343","Orphanet_180","EFO_0000685","HP_0002140","EFO_0009783","EFO_0003770","EFO_0003060","EFO_0000311","EFO_0003106","EFO_0000589","EFO_0000713","MONDO_0005301","EFO_0000095","MONDO_0005147","MONDO_0004975","EFO_0008583","EFO_0000612","MONDO_0021118"],"count":120},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 10 approved and 92 investigational indications."}
{"id":"CHEMBL1079576","canonicalSmiles":"NC(=O)OCCCc1ccccc1","inchiKey":"CAMYKONBWHRPDD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENPROBAMATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MH-532","NSC-44682","NSC-50538","NSC-64270","Phenprobamate","Spantol"],"crossReferences":{"PubChem":["144205768","170465902","26758011","49674599"],"Wikipedia":["Phenprobamate"],"drugbank":["DB13354"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1085","canonicalSmiles":"CC(=O)c1ccc2c(c1)N(CCCN1CCN(CCO)CC1)c1ccccc1S2","inchiKey":"WNTYBHLDCKXEOT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACETOPHENAZINE","yearOfFirstApproval":1961,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Acetophenazine","Tindal"],"crossReferences":{"PubChem":["50125831"],"Wikipedia":["Acetophenazine"],"drugbank":["DB01063"],"chEBI":["2401"]},"childChemblIds":["CHEMBL2360079"],"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["EFO_0005407"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1961 and is indicated for psychosis."}
{"id":"CHEMBL1199080","canonicalSmiles":"CC[N+](C)(C)Cc1ccccc1Br","inchiKey":"AAQOQKQBGPPFNS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BRETYLIUM","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Bretylium","Bretylium cation","Bretylium ion"],"crossReferences":{"PubChem":["50113154","50113155"],"Wikipedia":["Bretylium"],"drugbank":["DB01158"],"chEBI":["3172"]},"childChemblIds":["CHEMBL1095292"],"linkedTargets":{"rows":["ENSG00000103546"],"count":1},"linkedDiseases":{"rows":["EFO_0004269","EFO_0004287","HP_0004308"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and has 3 approved indications."}
{"id":"CHEMBL1200387","canonicalSmiles":"CC(N)Cc1ccccc1.O=C(O)CCCCC(=O)O","inchiKey":"OFCJKOOVFDGTLY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMPHETAMINE ADIPATE","yearOfFirstApproval":1975,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL405","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Amphetamine adipate"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1975."}
{"id":"CHEMBL1200412","canonicalSmiles":"C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2OC(=O)CCc1ccccc1","inchiKey":"UBWXUGDQUBIEIZ-QNTYDACNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NANDROLONE PHENPROPIONATE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Durabolin","Nandrolone phenpropionate"],"synonyms":["Nandrolone phenpropionate","Nandrolone phenylpropionate","Norandrostenolone phenylpropionate","Nortestosterone furanpropionate","Nortestosterone phenylpropionate"],"crossReferences":{"PubChem":["144206893","170465193"],"drugbank":["DB00984"],"chEBI":["7468"]},"linkedTargets":{"rows":["ENSG00000169083"],"count":1},"linkedDiseases":{"rows":["EFO_0003966"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959 and is indicated for eye disease."}
{"id":"CHEMBL1200483","canonicalSmiles":"CC1NCCOC1c1ccccc1.Cl","inchiKey":"VJNXVAVKCZJOFQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENMETRAZINE HYDROCHLORIDE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201208","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Preludin"],"synonyms":["NSC-405728","Phenmetraline hydrochloride","Phenmetrazine chloride","Phenmetrazine hcl","Phenmetrazine hydrochloride"],"crossReferences":{"PubChem":["144205719","170465166"],"chEBI":["8068"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1200600","canonicalSmiles":"CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C","inchiKey":"FAOZLTXFLGPHNG-KNAQIMQKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUOROMETHOLONE","yearOfFirstApproval":1972,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fluaton","Fluor-op","Fml forte","Fml fte","Fml-neo","Oxylone"],"synonyms":["Fluorometholone","NSC-33001"],"crossReferences":{"DailyMed":["fluorometholone"],"PubChem":["144203991","144212910","170464629","56422125","855588","91286"],"Wikipedia":["Fluorometholone"],"drugbank":["DB00324"],"chEBI":["31625"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["HP_0007957","MP_0001845","EFO_1000906","HP_0009926","EFO_0009552","EFO_0003894","EFO_0005752"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1972 and has 4 approved and 2 investigational indications."}
{"id":"CHEMBL1200672","canonicalSmiles":"Cc1cc(O)c(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)[O-])=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)cn1.[Na+]","inchiKey":"RIWWMGQFMUUYIY-ALLHVENQSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFPIRAMIDE SODIUM","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201204","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cefpiramide sodium","Sepatren"],"synonyms":["Cefpiramide sodium","Cefpiramide sodium salt","Suncefal","WY-44,635 SODIUM","WY-44635"],"crossReferences":{"chEBI":["31377"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989."}
{"id":"CHEMBL1200810","canonicalSmiles":"C=C1/C(=C\\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O","inchiKey":"HKXBNHCUPKIYDM-CGMHZMFXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOXERCALCIFEROL","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Doxercalciferol","Hectorol"],"synonyms":["1-.alpha.-hydroxyergocalciferol","1-alpha-hydroxyergocalciferol","1-hydroxyergocalciferol","1.alpha.-hydroxyergocalciferol","1.alpha.-hydroxyvitamin d2","Doxercalciferol","GZ427397","TSA-840"],"crossReferences":{"DailyMed":["doxercalciferol"],"PubChem":["144206531"],"Wikipedia":["Doxercalciferol"],"drugbank":["DB06410"],"chEBI":["4712"]},"linkedTargets":{"rows":["ENSG00000111424"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_1001173","EFO_0003884","EFO_0000676","MONDO_0008315","EFO_0005754"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 3 approved and 3 investigational indications."}
{"id":"CHEMBL1200947","canonicalSmiles":"CC(=O)Oc1c(C)cc(OCC(O)CNC(C)C)c(C)c1C.Cl","inchiKey":"BLWNYSZZZWQCKO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METIPRANOLOL HYDROCHLORIDE","yearOfFirstApproval":1989,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1291","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"],"classes":["Opthalmic toxicity"],"year":1990},"tradeNames":["Metipranolol","Optipranolol"],"synonyms":["Betamann","Metipranolol hcl","Metipranolol hydrochloride"],"crossReferences":{"chEBI":["34845"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1989. It was withdrawn in United Kingdom  in 1990 due to Opthalmic toxicity."}
{"id":"CHEMBL1201302","canonicalSmiles":"C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O","inchiKey":"VQODGRNSFPNSQE-CXSFZGCWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEXAMETHASONE PHOSPHORIC ACID","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Dexamethasone phosphate","Dexamethasone phosphoric acid"],"crossReferences":{"DailyMed":["dexamethasone%20sodium%20phosphate"],"chEBI":["68637"]},"childChemblIds":["CHEMBL1200637","CHEMBL2021430"],"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","EFO_0005539","EFO_1000845","EFO_0010822","MONDO_0017634","HP_0000559","EFO_0004274","MONDO_0002959","EFO_0005558","EFO_0005773","EFO_0008997","EFO_0000565","EFO_0007160","EFO_0009456","EFO_0007520","EFO_0009560","EFO_0002690","EFO_0004255","EFO_0000676","EFO_0009552","EFO_0004276","EFO_1001250","EFO_0004719","HP_0003072","EFO_0005854","EFO_1000811","EFO_0009449","EFO_1000906","EFO_0001642","EFO_1000039","HP_0001742","EFO_0000384","HP_0001873","EFO_1001119","EFO_1002022","MP_0001845","MONDO_0100096","HP_0003040","Orphanet_90794","EFO_1000049","MONDO_0002406","EFO_0000574","MONDO_0004979","EFO_1001051","EFO_0001378","HP_0012424","EFO_0007328","EFO_1001222","EFO_0009491","MONDO_0003005","EFO_0007405","EFO_1001896","EFO_1000997","EFO_1001205","EFO_0005319","EFO_1000764","MONDO_0001280","EFO_1001435","HP_0001094","EFO_0003778","EFO_1000684","EFO_0009509","EFO_0000274","HP_0001915","HP_0004398","MONDO_0001718","EFO_1000694","MONDO_0005129","EFO_0005752","EFO_0007490","EFO_0009609","Orphanet_797","EFO_0000694","EFO_0000685","MONDO_0015128","EFO_0003898","EFO_0000556","EFO_0003929","EFO_0001358","EFO_0003894","EFO_0003843","EFO_1000941","EFO_0002609","EFO_0000311","EFO_0006738","EFO_0003106","EFO_0007257","EFO_0007403","EFO_1001194","EFO_0007141","MONDO_0005178","EFO_0004265","EFO_0003956"],"count":93},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 68 approved and 15 investigational indications."}
{"id":"CHEMBL1201409","drugType":"Protein","blackBoxWarning":false,"name":"TECHNETIUM TC 99M ALBUMIN COLLOID","yearOfFirstApproval":1983,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Microlite"],"synonyms":["Technetium tc 99m albumin colloid","Technetium tc-99m albumin colloid kit"],"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 1983."}
{"id":"CHEMBL1201891","canonicalSmiles":"CC(=O)OCC(=O)[C@@]12N=C(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C","inchiKey":"FBHSPRKOSMHSIF-GRMWVWQJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEFLAZACORT","yearOfFirstApproval":2017,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Calcort","Emflaza","Zamene"],"synonyms":["Deflazacort","MDL 458","MDL-458","MDL458"],"crossReferences":{"DailyMed":["deflazacort"],"PubChem":["144206059","144211732","170466610"],"drugbank":["DB11921"]},"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["Orphanet_98896","EFO_0003086","Orphanet_263","Orphanet_268","EFO_1001216","EFO_0001421","EFO_0003884","EFO_0007140","Orphanet_98473","Orphanet_45448"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2017 and is indicated for duchenne muscular dystrophy and muscular dystrophy and has 4 investigational indications."}
{"id":"CHEMBL1206212","canonicalSmiles":"O=C(O)COc1ccc(-c2cnc(CNC(=O)Nc3ncc(Sc4ccccn4)s3)[nH]2)cc1","inchiKey":"SSXCWVOQWRUMGN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1206212","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08657"]},"childChemblIds":["CHEMBL242241"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1206869","canonicalSmiles":"O=S(=O)(O)c1ccc2cc(S(=O)(=O)O)ccc2c1","inchiKey":"FITZJYAVATZPMJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1206869","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04640"],"chEBI":["41070"]},"childChemblIds":["CHEMBL319726"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1213353","canonicalSmiles":"CC[N+]1(CC)CCC(=C(c2ccccc2)c2ccccc2)C1C.[Br-]","inchiKey":"UCGJZJXOPSNTGZ-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"PRIFINIUM BROMIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL1229214","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PDB","Padrin","Prifinium bromide","Pyrodifenium bromide","Riabal"],"crossReferences":{"PubChem":["144206846"],"Wikipedia":["Prifinium_bromide"],"chEBI":["32052"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1234004","canonicalSmiles":"[Li+]","inchiKey":"HBBGRARXTFLTSG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LITHIUM ION","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01356"],"chEBI":["49713"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236394","canonicalSmiles":"O=C(O)CC(CC(=O)O)C(=O)O","inchiKey":"KQTIIICEAUMSDG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRICARBALLYLIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["4252467","69020"],"drugbank":["DB04562"],"chEBI":["45969"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1275868","canonicalSmiles":"CC1=C(C(=O)OC(C)C)C(c2cccc([N+](=O)[O-])c2)C(C(=O)OC2CN(C(c3ccccc3)c3ccccc3)C2)=C(N)N1","inchiKey":"ZKFQEACEUNWPMT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZELNIDIPINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Azelnidipine","Calblock"],"crossReferences":{"PubChem":["144205993","170465756","174006618","50112690"],"drugbank":["DB09230"]},"linkedTargets":{"rows":["ENSG00000157388","ENSG00000081248","ENSG00000151067","ENSG00000102001"],"count":4},"linkedDiseases":{"rows":["EFO_0000537"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL142703","canonicalSmiles":"N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2","inchiKey":"SYOKIDBDQMKNDQ-XWTIBIIYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VILDAGLIPTIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Galvus"],"synonyms":["LAF 237","LAF-237","LAF237","NVP-LAF 237","NVP-LAF237","Vildagliptin","Vitagliptin"],"crossReferences":{"Wikipedia":["Vildagliptin"],"drugbank":["DB04876"]},"linkedTargets":{"rows":["ENSG00000197635"],"count":1},"linkedDiseases":{"rows":["HP_0100543","EFO_0004593","EFO_1001459","MONDO_0002009","EFO_1001121","MONDO_0005147","MONDO_0005148","EFO_0000400","EFO_0002546"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for diabetes mellitus and has 6 investigational indications."}
{"id":"CHEMBL1597","canonicalSmiles":"OCC(S)CS","inchiKey":"WQABCVAJNWAXTE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIMERCAPROL","yearOfFirstApproval":1946,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Anti-Lewisite","B.a.l.","Sulfactin"],"synonyms":["1-propanol, 2,3-dimercapto","2,3,-dimercapto-1-propanol","2,3-dithiopropan-1-ol","2,3-dithiopropanol","Antoxol","Bal","Dicaptol","Dimercaprol","Dimercaprolum","Dimersol","NSC-39515","NSC-4646","Panobal","Sulfactin"],"crossReferences":{"DailyMed":["dimercaprol"],"PubChem":["144203565"],"Wikipedia":["Dimercaprol"],"drugbank":["DB06782"],"chEBI":["64198"]},"childChemblIds":["CHEMBL1968682"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1946."}
{"id":"CHEMBL1609891","canonicalSmiles":"CCCC[S+](=N)([O-])CC[C@H](N)C(=O)O","inchiKey":"WDFRNLYXRQXXFS-CVSPRKDYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUTHIONINE SULFOXIMINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Buthionine sulfoxamine","Buthionine sulfoximine","Butionine sulfoximine","Dl-buthionine (s,r)-sulfoximine","L-Buthionine(S,R)-Sulfoximine","L-Buthionine-Sulfoximine","NSC-381100"],"crossReferences":{"PubChem":["90341329"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1614709","canonicalSmiles":"Cc1cc(Nc2ncc(F)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc1N1CCN(C)CC1","inchiKey":"KSOVGRCOLZZTPF-QMKUDKLTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CENISERTIB","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AS-703569","R-763"],"crossReferences":{"drugbank":["DB06347"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1618279","canonicalSmiles":"Cc1nc(Nc2ccc(F)cc2)nc(N2CCc3ccccc3C2C)c1C","inchiKey":"LECZXZOBEZITCL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"REVAPRAZAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Revaprazan","SB-641257","YH-1885 FREE BASE"],"childChemblIds":["CHEMBL1257753"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1664","canonicalSmiles":"CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1","inchiKey":"MLBVMOWEQCZNCC-OEMFJLHTSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOSAMPRENAVIR","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Fosamprenavir","GW-433908","GW433908","GW433908A"],"crossReferences":{"DailyMed":["fosamprenavir%20calcium"],"Wikipedia":["Fosamprenavir"],"drugbank":["DB01319"],"chEBI":["82941"]},"childChemblIds":["CHEMBL2106751","CHEMBL1200734"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 3 approved and 4 investigational indications."}
{"id":"CHEMBL1741040","canonicalSmiles":"CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N1[C@@H](C)CCC[C@H]1C)C(=O)O","inchiKey":"LPAHKJMGDSJDRG-DJYQTOCQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BQ 788","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bq 788"],"childChemblIds":["CHEMBL1515091"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1742985","drugType":"Antibody","blackBoxWarning":false,"name":"ANRUKINZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anrukinzumab","IMA-638"],"linkedTargets":{"rows":["ENSG00000169194"],"count":1},"linkedDiseases":{"rows":["EFO_0000729","MONDO_0004979"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1743088","drugType":"Antibody","blackBoxWarning":false,"name":"VELTUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HA20","IMMU-106","Veltuzumab"],"linkedTargets":{"rows":["ENSG00000156738"],"count":1},"linkedDiseases":{"rows":["EFO_0007160","EFO_0000685","MONDO_0000432","EFO_0000095","EFO_0000220","EFO_0000403","EFO_0000574","MONDO_0018906","EFO_0005952"],"count":9},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL1746","canonicalSmiles":"O=C([O-])CCCc1ccccc1.[Na+]","inchiKey":"VPZRWNZGLKXFOE-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"SODIUM PHENYLBUTYRATE","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1469","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ambutyrate","Ammonaps","Buphenyl","Pheburane","Sodium phenylbutyrate"],"synonyms":["ACER-001","AMX-0035 COMPONENT SODIUM PHENYLBUTYRATE","AMX0035 COMPONENT SODIUM PHENYLBUTYRATE","NSC-657802","Sodium phenylbutyrate"],"crossReferences":{"DailyMed":["sodium%20phenylbutyrate"],"PubChem":["170465108","507865"],"Wikipedia":["Sodium_phenylbutyrate"],"chEBI":["75316"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 3 approved and 13 investigational indications."}
{"id":"CHEMBL1766582","canonicalSmiles":"Cl.Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21","inchiKey":"RQHSAIGGUWVOBG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"R-1487","maximumClinicalTrialPhase":1,"parentId":"CHEMBL1230122","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["R 1487","R-1487"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL181886","canonicalSmiles":"CC(=O)C(=O)[O-].[Na+]","inchiKey":"DAEPDZWVDSPTHF-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"PYRUVATE SODIUM","maximumClinicalTrialPhase":2,"parentId":"CHEMBL1162144","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pyruvate sodium","Sodium 2-Oxo-Propionate","Sodium 2-Oxopropanoate"],"crossReferences":{"PubChem":["144211803"],"Wikipedia":["Sodium_pyruvate"],"chEBI":["50144"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1908906","canonicalSmiles":"CNc1ccc(/C=C/c2ccc(OCCOCCOCCF)cc2)cc1","inchiKey":"NCWZOASIUQVOFA-NSCUHMNNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLORBETABEN","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Florbetaben"],"crossReferences":{"DailyMed":["florbetaben%20f-18"]},"childChemblIds":["CHEMBL566752"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for cognitive impairment and alzheimer disease and has 2 investigational indications."}
{"id":"CHEMBL203266","canonicalSmiles":"COc1ccc(CN2CCNCC2)c(OC)c1OC","inchiKey":"UHWVSEOVJBQKBE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIMETAZIDINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vastarel","Vastarel mr"],"synonyms":["40045","Dilatan","Trimetazidine"],"crossReferences":{"PubChem":["11112605","56423815"],"Wikipedia":["Trimetazidine"],"drugbank":["DB09069"]},"childChemblIds":["CHEMBL1476337","CHEMBL3561076"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 7 investigational indications."}
{"id":"CHEMBL2035187","canonicalSmiles":"C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1","inchiKey":"HWXVIOGONBBTBY-ONEGZZNKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PACRITINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ONX-0803","Pacritinib","SB-1518","SB1518","Sb-1518"],"crossReferences":{"drugbank":["DB11697"]},"linkedTargets":{"rows":["ENSG00000096968","ENSG00000122025"],"count":2},"linkedDiseases":{"rows":["MONDO_0013730","MONDO_0044903","MONDO_0019457","MONDO_0007254","EFO_0000222","EFO_1001469","EFO_0003060","MONDO_0008315","EFO_1001951","EFO_0002430","EFO_0000565","EFO_0004251","MONDO_0100096","EFO_0000095","EFO_0000183"],"count":15},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."}
{"id":"CHEMBL205098","canonicalSmiles":"COc1cc(Nc2ncc3ccn(-c4ccccn4)c3n2)cc(OC)c1OC","inchiKey":"YENZSPIOXMNEFF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL205098","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07248"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL20767","canonicalSmiles":"N=C(N)Nc1ccc(C(=O)O)cc1","inchiKey":"SXTSBZBQQRIYCU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-GUANIDINO-BENZOIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-Amino(Immino)Methylaminobenzoate","4-Guanidino-Benzoic Acid","4-Guanidinobenzoic Acid"],"crossReferences":{"drugbank":["DB02459"],"chEBI":["125204"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2103979","canonicalSmiles":"CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(C)=O)C(C)C)[C@@H](C)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)O)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O","inchiKey":"NZVYCXVTEHPMHE-ZSUJOUNUSA-N","drugType":"Protein","blackBoxWarning":false,"name":"THYMALFASIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Zadaxin"],"synonyms":["Thymalfasin","Thymosin alpha1","Thymosins thymalfasin"],"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 14 investigational indications."}
{"id":"CHEMBL2104030","canonicalSmiles":"COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1c1ccccc1[N+](=O)[O-]","inchiKey":"NCUCGYYHUFIYNU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ARANIDIPINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aranidipine","MPC-1304","Sapresta"],"crossReferences":{"PubChem":["124893774","144206554","170465977"],"drugbank":["DB09229"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2105487","canonicalSmiles":"[S]","inchiKey":"NINIDFKCEFEMDL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFUR, PRECIPITATED","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Acnaveen","Acnil","Bensulfoid","Cuticura","Dome-acne","Eskamel","Liquamat","Meted","Sastid","Sulfur soap"],"synonyms":[".alpha.-sulfur","Colloidal sulfur","Colloidal sulphur","Liu huang","NSC-603623","Orthorhombic sulfur","Sulfur","Sulfur (s8)","Sulfur compounds","Sulfur precipitated","Sulfur, colloidal","Sulfur, precipitated","Sulfur, sublimed","Sulfur,colloidal","Sulfur,micronized","Sulfur,precipitated","Sulfur,sublimed"],"crossReferences":{"chEBI":["26833"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for acne and pruritus."}
{"id":"CHEMBL2105961","canonicalSmiles":"CN(C)CC(CN1c2ccccc2Sc2ccccc21)N(C)C","inchiKey":"YZQNFFLGIYEXMM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMINOPROMAZINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aminopromazine","Aminopropazine","Proquamezine","Tetrameprozine"],"crossReferences":{"drugbank":["DB15596"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106660","canonicalSmiles":"C1CNCCN1.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O.Cn1c(=O)c2c(ncn2CC(=O)O)n(C)c1=O","inchiKey":"HAAJFUJFGYCCPU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACEFYLLINE PIPERAZINE","maximumClinicalTrialPhase":4,"parentId":"CHEMBL70246","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Etophylate"],"synonyms":["Acefylline piperazine","Acepifylline","Dynaphylline","Epicophylline","Etafillina","Etaphylline","Piperazine theophylline ethanoate"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for airway obstruction."}
{"id":"CHEMBL2107495","canonicalSmiles":"CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1.Cl","inchiKey":"DDVJEYDLTXRYAJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEMAFLOXACIN HYDROCHLORIDE","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL277100","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"," United Kingdom"," Germany"],"classes":["Hematological toxicity"," Hepatotoxicity"," Immune system toxicity"," Nephrotoxicity"],"year":1992},"tradeNames":["Omnifiox","Teflox","Teflox 400"],"synonyms":["ABBOTT-62254","Temafloxacin hcl","Temafloxacin hydrochloride"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992. It was withdrawn in United States,  United Kingdom and  Germany initially in 1992 due to Hematological toxicity,  Hepatotoxicity,  Immune system toxicity and  Nephrotoxicity."}
{"id":"CHEMBL2108113","drugType":"Small molecule","blackBoxWarning":false,"name":"SESAME OIL","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mayou","Oleum sesami","Sesame","Sesame oil","Sesamum indicum (sesame) seed butter","Sesamum indicum oil","Sesamum indicum seed oil"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2108304","drugType":"Gene","blackBoxWarning":false,"name":"ALIPOGENE TIPARVOVEC","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Alipogene tiparvovec","Glybera"],"crossReferences":{"DrugCentral":["5172"]},"description":"Gene drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cardiovascular disease and has 1 investigational indication."}
{"id":"CHEMBL2108356","drugType":"Protein","blackBoxWarning":false,"name":"PEGDINETANIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Angiocept","BMS-844203","CT-322","Ct-322","Pegdinetanib","VEGFR-2 INHIBITOR PEPTIDE CT-322"],"linkedTargets":{"rows":["ENSG00000128052"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000365","EFO_0000519","EFO_0003060","EFO_0000311"],"count":5},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2108734","drugType":"Antibody","blackBoxWarning":false,"name":"FLANVOTUMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["20-D-7S","20D7S","Flanvotumab","IMC-20D7S","IMC20D7S"],"linkedTargets":{"rows":["ENSG00000107165"],"count":1},"linkedDiseases":{"rows":["EFO_0000756"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109090","drugType":"Antibody","blackBoxWarning":false,"name":"ENLIMOMAB","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BI-RR-0001","Enlimomab"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2109259","drugType":"Antibody","blackBoxWarning":false,"name":"IGN-101","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IGN-101"],"description":"Antibody drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2109408","drugType":"Antibody","blackBoxWarning":false,"name":"LAMPALIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AFD","Anti-fD","FCFD-4514S","FCFD4514S","Lampalizumab","RG-7417","RG7417","Sn578b8z9q","anti-FACTOR-D"],"linkedTargets":{"rows":["ENSG00000197766"],"count":1},"linkedDiseases":{"rows":["EFO_0001365"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2109501","drugType":"Antibody","blackBoxWarning":false,"name":"IGN-311","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["IGN-311"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2109571","drugType":"Antibody","blackBoxWarning":false,"name":"AMG-167","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG-167","Amg-167"],"linkedTargets":{"rows":["ENSG00000167941"],"count":1},"linkedDiseases":{"rows":["HP_0000938"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109617","drugType":"Antibody","blackBoxWarning":false,"name":"HUMAX-IL8","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-986253","HUMAX-IL8","Humax-il-8","Humax-il8","Humax-inflam","MDX-018"],"linkedTargets":{"rows":["ENSG00000169429"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","EFO_0002618","MONDO_0100096","EFO_0000182","EFO_0000673","EFO_0000181","EFO_0000311"],"count":8},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL2109677","drugType":"Antibody","blackBoxWarning":false,"name":"HUJ591 111IN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HUJ591","Huj591 (111in)","Huj591 111in"],"linkedTargets":{"rows":["ENSG00000086205"],"count":1},"linkedDiseases":{"rows":["MONDO_0008315"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2110588","canonicalSmiles":"CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2c(c1)OCCO2","inchiKey":"FJZZPCZKBUKGGU-AUSIDOKSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ELIGLUSTAT","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cerdelga"],"synonyms":["Eliglustat","GENZ 99067","GENZ-99067"],"crossReferences":{"DailyMed":["eliglustat%20tartrate"],"drugbank":["DB09039"],"chEBI":["82752"]},"childChemblIds":["CHEMBL4297066"],"linkedTargets":{"rows":["ENSG00000148154"],"count":1},"linkedDiseases":{"rows":["Orphanet_77259","Orphanet_355","MONDO_0044881","Orphanet_77261"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for gaucher disease and has 4 investigational indications."}
{"id":"CHEMBL212689","canonicalSmiles":"CCN(C(=O)Cc1ccc(S(C)(=O)=O)cc1)C1CCN(CC[C@H](c2ccc(S(C)(=O)=O)cc2)c2cc(F)cc(F)c2)CC1","inchiKey":"SCXSQUUTGCWHFU-WJOKGBTCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL212689","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB11804"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL222559","canonicalSmiles":"CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1","inchiKey":"SUJUHGSWHZTSEU-FYBSXPHGSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TIPRANAVIR","yearOfFirstApproval":2005,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Aptivus"],"synonyms":["Tipranavir","U-140690"],"crossReferences":{"DailyMed":["tipranavir"],"PubChem":["144206515"],"drugbank":["DB00932"],"chEBI":["63628"]},"childChemblIds":["CHEMBL445699","CHEMBL2103936"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and has 3 approved indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL225986","canonicalSmiles":"O=C(O)C[C@@H](O)C(=O)O","inchiKey":"BJEPYKJPYRNKOW-UWTATZPHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"(R)-2-Hydroxysuccinic Acid","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(R)-2-Hydroxysuccinic Acid"],"crossReferences":{"PubChem":["8139952"],"drugbank":["DB03499"],"chEBI":["30796"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL230153","canonicalSmiles":"CCc1nc(N)nc(N)c1-c1ccc(NCc2cc(F)cc(F)c2)cc1","inchiKey":"SRRWXMSVQYQCRX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL230153","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07244"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL231950","canonicalSmiles":"C/C(=C1/SC(=N)NC1=O)c1ccc(-c2ccc(S(N)(=O)=O)cc2)o1","inchiKey":"AKFVRSQELXTCFW-JYRVWZFOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL231950","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07540"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL233360","canonicalSmiles":"N[C@H]1C[C@@H](N2CCn3c(nnc3C(F)(F)F)C2)CC[C@@H]1c1cc(F)c(F)cc1F","inchiKey":"CNKRZILQBKJWDS-WMFXKJRFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL233360","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07072"],"chEBI":["39959"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2364653","drugType":"Antibody","blackBoxWarning":false,"name":"ANIFROLUMAB","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Saphnelo"],"synonyms":["Anifrolumab","Anifrolumab-fnia","MEDI-546"],"linkedTargets":{"rows":["ENSG00000142166"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","EFO_0005761","EFO_0002690","EFO_1001993"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for systemic lupus erythematosus and has 3 investigational indications."}
{"id":"CHEMBL236573","canonicalSmiles":"CC#CCNc1ccc(S(=O)(=O)CC2(C(=O)NO)CCN(C(=O)OC(C)(C)C)CC2)cc1","inchiKey":"RXFCFGLSOUOCEA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL236573","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07013"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL254857","canonicalSmiles":"O=C(COc1ccc(Cl)cc1)N1CCN(Cc2ccc3c(c2)OCO3)CC1","inchiKey":"BFUJHVVEMMWLHC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FIPEXIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["France"],"classes":["Hepatotoxicity"],"year":1991},"tradeNames":[],"synonyms":["Fipexide","NSC-758407"],"crossReferences":{"PubChem":["11112737","49716199"],"Wikipedia":["Fipexide"],"drugbank":["DB13790"]},"childChemblIds":["CHEMBL1377408"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for attention deficit hyperactivity disorder. It was withdrawn in France  in 1991 due to Hepatotoxicity."}
{"id":"CHEMBL256105","canonicalSmiles":"CC[C@@]1([C@@H]2O[C@@H]([C@H]3O[C@@](O)(CO)[C@H](C)C[C@@H]3C)C[C@@H]2C)CC[C@H]([C@]2(C)CC[C@]3(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(=O)O)O3)O2)O1","inchiKey":"GAOZTHIDHYLHMS-KEOBGNEYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MONENSIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Coban [as sodium salt]","Rumensin [as sodium salt]"],"synonyms":["67314","A-3823A","E714","Monensin"],"crossReferences":{"Wikipedia":["Monensin"],"drugbank":["DB11430"],"chEBI":["27617"]},"childChemblIds":["CHEMBL1908308"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL260538","canonicalSmiles":"CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C","inchiKey":"OOLLAFOLCSJHRE-ZHAKMVSLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ULIPRISTAL ACETATE","yearOfFirstApproval":2010,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ella","Ellaone","Esmya"],"synonyms":["CDB-2914","PGL-4001","RTI-3021-012","Ulipristal acet","Ulipristal acetate","Ulipristal acetate ","VA-2914","VA2914"],"crossReferences":{"DailyMed":["ulipristal%20acetate"],"Wikipedia":["Ulipristal_acetate"],"chEBI":["71025"]},"linkedTargets":{"rows":["ENSG00000082175"],"count":1},"linkedDiseases":{"rows":["MP_0001914","EFO_0000545","MONDO_0002050","MONDO_0004169","EFO_0000731","EFO_1001757","MONDO_0007254","MONDO_0001572","Orphanet_101081","HP_0001892","EFO_0003922"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and has 9 investigational indications."}
{"id":"CHEMBL267048","canonicalSmiles":"O=P(O)(O)C(F)(F)c1ccc(CC(Cc2ccc(C(F)(F)P(=O)(O)O)cc2)(c2ccc(F)c(F)c2)n2nnc3ccccc32)cc1","inchiKey":"BTAGTGWPDROBMG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL267048","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02651"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL268736","canonicalSmiles":"CCCCC(=O)O","inchiKey":"NQPDZGIKBAWPEJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VALERIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Butane-1-carboxylic acid","Pentanoic acid"],"crossReferences":{"PubChem":["144208759","144213347","47193677"],"Wikipedia":["Valeric_acid"],"drugbank":["DB02406"],"chEBI":["17418"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL270995","canonicalSmiles":"Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)OC(=O)[C@H](C)N)c(C)c34)ccc2[nH]1","inchiKey":"LTEJRLHKIYCEOX-OCCSQVGLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BRIVANIB ALANINATE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-582664","BMS-582664-02","Brivanib alaninate","Brivanib l-alanine ester"],"crossReferences":{"drugbank":["DB11865"]},"childChemblIds":["CHEMBL3526472"],"linkedTargets":{"rows":["ENSG00000128052","ENSG00000066468","ENSG00000068078","ENSG00000102755","ENSG00000077782","ENSG00000037280","ENSG00000160867"],"count":7},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000681","EFO_0000182","EFO_1001951","EFO_0000311"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL28218","canonicalSmiles":"O=C(CCCN1CCC(O)(c2ccc(Br)cc2)CC1)c1ccc(F)cc1","inchiKey":"RKLNONIVDFXQRX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BROMPERIDOL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Impromen"],"synonyms":["Bromperidol","NSC-759275","R 11,333","R-11333"],"crossReferences":{"PubChem":["11112600","144204116","170465873","56463221"],"Wikipedia":["Bromperidol"],"drugbank":["DB12401"]},"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0002050","HP_0000726","EFO_0005407","EFO_0005230","EFO_0005411"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for psychosis and has 4 investigational indications."}
{"id":"CHEMBL287556","canonicalSmiles":"O=c1cc(CO)occ1O","inchiKey":"BEJNERDRQOWKJM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"KOJIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5-Hydroxy-2-(hydroxymethyl)-4-pyrone","Kojic acid"],"crossReferences":{"PubChem":["104171348","144204365","144206999","170466814","26754136"],"Wikipedia":["Kojic_acid"],"drugbank":["DB01759"],"chEBI":["43572"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL292411","canonicalSmiles":"O=C(O)[C@H](O)c1ccccc1","inchiKey":"IWYDHOAUDWTVEP-SSDOTTSWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Hydroxy-Phenyl-Acetic Acid Anion","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hydroxy-Phenyl-Acetic Acid Anion"],"crossReferences":{"PubChem":["170465573","26513819"],"drugbank":["DB02280"],"chEBI":["17656"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL305544","canonicalSmiles":"CCc1nc(C2CC2)c(C(N)=O)n1Cc1ccc2oc(-c3ccccc3NS(=O)(=O)C(F)(F)F)c(Br)c2c1","inchiKey":"DUEWVPTZCSAMNB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SAPRISARTAN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GR-138950","Saprisartan"],"crossReferences":{"drugbank":["DB01347"]},"childChemblIds":["CHEMBL3989726"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL308333","canonicalSmiles":"CCCCC[C@H](CC(=O)NO)C(=O)N[C@H](C(=O)N1CCC[C@H]1CO)C(C)C","inchiKey":"XJLATMLVMSFZBN-VYDXJSESSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACTINONIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Actinonin"],"crossReferences":{"PubChem":["50105725","50105726","50105727","90341343"],"Wikipedia":["Actinonin"],"drugbank":["DB04310"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3137305","canonicalSmiles":"CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1.Cl","inchiKey":"RCHQNUQAHJNRBY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DEFACTINIB HYDROCHLORIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL3137331","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Defactinib hydrochloride","VS-6063","VS-6063 HYDROCHLORIDE"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL314010","canonicalSmiles":"COc1ccc(CCNCC(O)COc2cccc(C)c2)cc1OC","inchiKey":"HXLAFSUPPDYFEO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BEVANTOLOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bevantolol","NSC-132348"],"crossReferences":{"Wikipedia":["Bevantolol"],"drugbank":["DB01295"],"chEBI":["238698"]},"childChemblIds":["CHEMBL2106060"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL31601","canonicalSmiles":"CC(C)(C)S(=O)(=O)C[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC1CCCCC1)[C@@H](O)[C@@H](O)C1CC1","inchiKey":"UXIGZRQVLGFTOU-VQXQMPIVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"REMIKIREN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RO 42-5892","RO-42-5892","Remikiren"],"crossReferences":{"Wikipedia":["Remikiren"],"drugbank":["DB00212"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3182320","canonicalSmiles":"C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(OCCO)c(OCCO)c4)oc4cc(OCCO)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O","inchiKey":"IYVFNTXFRYQLRP-VVSTWUKXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TROXERUTIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["3',4',7-tris(hydroxyethyl)rutin","Flavonoid","NSC-758937","THR","Trioxyethylrutin","Troxerutin","Vitamin p4","Z 6000","Z-6000"],"crossReferences":{"PubChem":["144205003"],"drugbank":["DB13124"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3184454","canonicalSmiles":"NCCC(=O)N1[Zn]OC(=O)[C@@H]1Cc1cnc[nH]1","inchiKey":"IGXZLYMCFZHNKW-FJXQXJEOSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3184454","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144206503"],"drugbank":["DB09221"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3184799","canonicalSmiles":"CNC(C)(C)Cc1ccccc1.CNC(C)(C)Cc1ccccc1.O=S(=O)(O)O","inchiKey":"DNKCFBJMFIUNRS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MEPHENTERMINE SULFATE","yearOfFirstApproval":1951,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201234","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Wyamine sulfate"],"synonyms":["Mephentermine sulfate","Mephentermine sulfate dihydrate","Mephentermine sulphate","Mephine","NSC-758424","Wyamine","Wyamine sulphate"],"crossReferences":{"PubChem":["144204052","170465271"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1951."}
{"id":"CHEMBL326082","canonicalSmiles":"C#CCCCn1c(Cc2cc(OC)ccc2OC)nc2c(N)nc(F)nc21","inchiKey":"RMOYVWKKOKERSW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL326082","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03137"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3301620","canonicalSmiles":"COc1cnc(-n2cnc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(C(=O)c4ccccc4)CC3)c12","inchiKey":"QRPZBKAMSFHVRW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEMSAVIR","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-626529","Temsavir"],"crossReferences":{"drugbank":["DB14675"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL346059","canonicalSmiles":"O=c1[nH]c2ccccc2c(=O)o1","inchiKey":"TXJUTRJFNRYTHH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL346059","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144208523","144213375"],"drugbank":["DB11593"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL346977","canonicalSmiles":"CC(CN1c2ccccc2Sc2ccc(S(=O)(=O)N(C)C)cc21)N(C)C","inchiKey":"VWNWVCJGUMZDIU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FONAZINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Banistyl"],"synonyms":["8599 R.P.","Dimetotiazine","IL-6302","Migristene"],"crossReferences":{"PubChem":["144206752"],"drugbank":["DB08967"]},"childChemblIds":["CHEMBL2104669"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for migraine disorder."}
{"id":"CHEMBL3544926","drugType":"Antibody","blackBoxWarning":true,"name":"OBILTOXAXIMAB","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Anthim"],"synonyms":["ETI-204","Obiltoxaximab"],"crossReferences":{"DailyMed":["obiltoxaximab"],"DrugCentral":["5094"]},"description":"Antibody drug with a maximum clinical trial phase of IV that was first approved in 2016 and is indicated for anthrax infection. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3545002","drugType":"Small molecule","blackBoxWarning":false,"name":"MP-412","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AV-412","Mp 412","Mp-412"],"linkedTargets":{"rows":["ENSG00000146648","ENSG00000141736"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000311"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3622820","canonicalSmiles":"N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1","inchiKey":"KTBSXLIQKWEBRB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ITACITINIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["INCB-039110","INCB039110","Incb-039110","Incb-39110","Itacitinib"],"crossReferences":{"drugbank":["DB12154"]},"childChemblIds":["CHEMBL3948879","CHEMBL3707409","CHEMBL3947131"],"linkedTargets":{"rows":["ENSG00000162434"],"count":1},"linkedDiseases":{"rows":["MONDO_0009348","EFO_0000729","HP_0000989","MONDO_0044903","EFO_0007183","EFO_0000756","MONDO_0007254","EFO_0000540","EFO_0004251","MONDO_0008903","EFO_0000182","MONDO_0015540","EFO_0000676","EFO_0000183","EFO_0000717","EFO_0005803","MONDO_0013730","EFO_0000616","EFO_0000685","EFO_0002618","MONDO_0044881","EFO_0004599","EFO_0003060","EFO_0000311","MONDO_0011962","EFO_0000574","EFO_1000560","MONDO_0024880"],"count":28},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 27 investigational indications."}
{"id":"CHEMBL369180","canonicalSmiles":"CC(=O)N(C)c1cccc(-c2nnc3ccc(-c4ccccc4)nn23)c1","inchiKey":"ALBWBHNFOJJMCV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL369180","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04154"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3707336","drugType":"Small molecule","blackBoxWarning":false,"name":"FERROUS CARBONATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ferrous carbonate","Ferrum carbonicum","Iron carbonate (feco3)","Siderite"],"crossReferences":{"DrugCentral":["4542"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL372507","canonicalSmiles":"Nc1nnc(S)s1","inchiKey":"GDGIVSREGUOIJZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL372507","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB12348"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3747513","canonicalSmiles":"Cc1cc2c(C(N)=O)cccc2n1-c1nc2c(c(NCc3ccccc3)n1)COCC2","inchiKey":"RDALZZCKQFLGJP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CB-5083","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cb 5083","Cb-5083"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL380331","canonicalSmiles":"NS(=O)(=O)c1ccc(Nc2cc(N[C@H]3CC[C@H](N)CC3)nc3ncnn23)cc1","inchiKey":"LVRKQJAEQWVSCM-HAQNSBGRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL380331","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07687"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL382300","canonicalSmiles":"CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]23OC(=O)O[C@H]2[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C1C3(C)C","inchiKey":"BWKDAMBGCPRVPI-ZQRPHVBESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ORTATAXEL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAY 59-8862","BAY-59-8862","IDN 5109","IDN-5109","Ortataxel","SB-T 101131","SB-T-101131"],"crossReferences":{"drugbank":["DB11669"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL393220","canonicalSmiles":"CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)[O-].[Ca+2]","inchiKey":"FQCKMBLVYCEXJB-MNSAWQCASA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"ATORVASTATIN CALCIUM","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1487","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Atorvastatin calcium","Lipitor"],"synonyms":["Atorvastatin calcium","Atorvastatin calcium (anhydrous)","Atorvastatin calcium anhydrous","Atorvastatin calcium hydrate","Atorvastatin calcium salt anhydrous","Atorvastatin calcium salt trihydrate","Atorvastatin calcium trihydrate","CI-981","NSC-758617"],"crossReferences":{"DailyMed":["atorvastatin%20calcium"],"PubChem":["144205238","144212690","170465113"],"chEBI":["50686"]},"linkedTargets":{"rows":["ENSG00000113161"],"count":1},"linkedDiseases":{"rows":["MONDO_0002492","EFO_0001361","EFO_0000365","MONDO_0001444","EFO_0000275","EFO_0000681","EFO_0005952","EFO_1000984","EFO_0003914","HP_0100543","EFO_0008585","EFO_0002690","EFO_0009952","EFO_0003884","EFO_0000676","EFO_0004616","EFO_1000961","EFO_0000400","EFO_0000198","MONDO_0013730","EFO_1000812","EFO_0000180","EFO_1001771","EFO_0004286","EFO_0004197","EFO_0000384","MONDO_0008315","EFO_0000660","EFO_0001422","EFO_0009426","EFO_0006818","MONDO_0000831","EFO_0000574","MONDO_0004979","EFO_0007328","EFO_0001378","EFO_0000341","EFO_0005672","EFO_0004214","MONDO_0018373","EFO_0003086","EFO_0001365","HP_0000726","MONDO_0007254","EFO_0004252","EFO_0008568","EFO_0000196","Orphanet_797","EFO_0000616","Orphanet_144","EFO_0000765","EFO_0004269","EFO_0001645","EFO_0000222","EFO_0003929","EFO_0000319","EFO_1001267","EFO_0004911","EFO_0000537","EFO_0000195","EFO_0004517","MONDO_0001134","MONDO_0021661","EFO_0000649","EFO_0000764","Orphanet_79211","MONDO_0011962","MONDO_0005148","EFO_0000519","EFO_0004265","EFO_0004264","EFO_0003869","EFO_0003095","EFO_0000266","EFO_0003913","EFO_0000565","EFO_0007160","EFO_0003870","EFO_0000182","EFO_0004208","HP_0003124","EFO_0002687","HP_0001919","EFO_1001466","Orphanet_3389","EFO_0004236","EFO_0004194","Orphanet_413","Orphanet_309005","HP_0002110","HP_0100806","MP_0001845","MONDO_0100096","MONDO_0021187","Orphanet_412","EFO_0000668","Orphanet_232","EFO_0000318","EFO_1001249","MONDO_0002679","EFO_0000373","EFO_0000538","EFO_0004246","Orphanet_68380","HP_0000083","EFO_0004211","EFO_0004247","EFO_0000474","EFO_1001801","EFO_1001375","EFO_0003144","EFO_0000712","EFO_0000673","EFO_1001993","HP_0003119","EFO_0003047","EFO_0007129","EFO_0008586","EFO_0000685","HP_0002140","EFO_0009783","EFO_0000556","HP_0001647","EFO_0002615","EFO_0000311","EFO_0000589","MONDO_0005301","MONDO_0004782","MONDO_0005147","MONDO_0004975","EFO_0008583","EFO_0000612","EFO_0003918"],"count":133},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 13 approved and 90 investigational indications."}
{"id":"CHEMBL3989410","canonicalSmiles":"COc1ccc2c(c1)c(CC(=O)[O-])c(C)n2C(=O)c1ccc(Cl)cc1.O.O.O.[Na+]","inchiKey":"UHYAQBLOGVNWNT-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"INDOMETHACIN SODIUM","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL6","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Indocin","Indomethacin sodium"],"synonyms":["Indometacin sodium","Indometacin sodium trihydrate","Indomethacin sodium","Indomethacin sodium salt trihydrate","Indomethacin sodium trihydrate","Sodium indomethacin trihydrate"],"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["MP_0001845"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1985 and has 1 investigational indication."}
{"id":"CHEMBL3989833","canonicalSmiles":"CS(=O)(=O)O.O.O.O.O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1","inchiKey":"WLQZEFFFIUHSJB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ZIPRASIDONE MESYLATE","yearOfFirstApproval":2002,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL708","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Geodon"],"synonyms":["CP-88, 059-27","CP-88,059-27","CP-88059-27","CP-8805927","NSC-760351","Ziprasidone mesilate","Ziprasidone mesilate trihydrate","Ziprasidone mesylate"],"crossReferences":{"DailyMed":["ziprasidone%20mesylate"]},"linkedTargets":{"rows":["ENSG00000149295","ENSG00000102468","ENSG00000147246"],"count":3},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0000289"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2002 and is indicated for bipolar disorder and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL404313","canonicalSmiles":"C[C@@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@@]2(C(=O)O)CC[C@H]1C","inchiKey":"JXSVIVRDWWRQRT-UYDOISQJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ASIATIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-88135"],"crossReferences":{"drugbank":["DB14054"],"chEBI":["2873"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL407","canonicalSmiles":"CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2","inchiKey":"OFBIFZUFASYYRE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"FLUMAZENIL","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Anexate","Flumazenil","Flumazepil","Mazicon","Romazicon"],"synonyms":["Flumazenil","Flumazepil","Lanexat","Mazicon","NSC-759193","RO 15-1788/000","RO-15-1788","RO-151788","RO-151788000","RO-1722","RO-41-8157"],"crossReferences":{"DailyMed":["flumazenil"],"PubChem":["104171157","11111184","11114035","11532958","170464960","26719655","26752172","26752173","50104818","56422177","85231047","90341071"],"Wikipedia":["Flumazenil"],"drugbank":["DB01205"],"chEBI":["5103"]},"linkedTargets":{"rows":["ENSG00000182256","ENSG00000022355","ENSG00000011677","ENSG00000113327","ENSG00000151834","ENSG00000163285","ENSG00000186297"],"count":7},"linkedDiseases":{"rows":["MONDO_0021107","EFO_0003890","MONDO_0005180","MONDO_0018044","EFO_1001884","EFO_0009267","EFO_0004242","MONDO_0007079","EFO_0005230","EFO_0004698","Orphanet_908"],"count":11},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1991 and has 9 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4081711","canonicalSmiles":"CC[C@H]1[C@@H](COc2nccc3cc(C(N)=O)c(OC)cc23)NC(=O)[C@H]1F","inchiKey":"JKDGKIBAOAFRPJ-ZBINZKHDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZIMLOVISERTIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF-06650833","Pf 06650833","Pf-06650833","Zimlovisertib"],"crossReferences":{"drugbank":["DB15143"]},"linkedTargets":{"rows":["ENSG00000198001"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","EFO_1000710","MONDO_0100096"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL411675","canonicalSmiles":"O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+]","inchiKey":"SEACYXSIPDVVMV-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"EOSIN Y SODIUM","maximumClinicalTrialPhase":0,"parentId":"CHEMBL376503","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Eosin Y Sodium"],"crossReferences":{"PubChem":["144205876","144212469","170466832"],"Wikipedia":["Eosin_Y"],"drugbank":["DB13706"],"chEBI":["52053"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4117187","canonicalSmiles":"COc1ccc2c(c1)c(CN1CCN(C)CC1)cn2S(=O)(=O)c1ccccc1Br","inchiKey":"GWCYPEHWIZXYFZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MASUPIRDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Masupirdine","SUVN-502","Suvn-502"],"crossReferences":{"drugbank":["DB06140"]},"childChemblIds":["CHEMBL4082473"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL411930","canonicalSmiles":"Cc1ccc(C)c(Cc2nn(C(C)(C)C)c3ncnc(N)c23)c1","inchiKey":"QUPXEJURIFFVSX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL411930","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08035"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL417","canonicalSmiles":"COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1","inchiKey":"AOJJSUZBOXZQNB-VTZDEGQISA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"EPIRUBICIN","yearOfFirstApproval":1999,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["4'-epi-adriamycin","Ellence","Epiadriamycin","Epidoxorubicin","Epirubicin","Farmorubicin","NSC-256942"],"crossReferences":{"DailyMed":["epirubicin%20hydrochloride"],"Wikipedia":["Epirubicin"],"drugbank":["DB00445"],"chEBI":["47898"]},"childChemblIds":["CHEMBL1200981"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1999 and has 4 approved and 46 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL425","canonicalSmiles":"O=C(O)c1cc(/N=N/c2ccc(O)c(C(=O)O)c2)ccc1O","inchiKey":"QQBDLJCYGRGAKP-FOCLMDBBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OLSALAZINE","yearOfFirstApproval":1990,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["C. i. mordant yellow 5","Dipentum","Olsalazine"],"crossReferences":{"DailyMed":["olsalazine%20sodium"],"PubChem":["50125747"],"drugbank":["DB01250"]},"childChemblIds":["CHEMBL1201013"],"linkedTargets":{"rows":["ENSG00000132170","ENSG00000073756","ENSG00000012779","ENSG00000095303"],"count":4},"linkedDiseases":{"rows":["EFO_0000729","EFO_0003898","HP_0004798"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1990 and is indicated for ulcerative colitis and has 1 investigational indication."}
{"id":"CHEMBL4297322","canonicalSmiles":"N#Cc1cc(CN2CCC(Nc3ncnc4sc(Cl)cc34)CC2)ccc1F.O=C(O)/C=C/C(=O)O","inchiKey":"RPYIKXHIQXRXEM-WLHGVMLRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRX-08066","maximumClinicalTrialPhase":2,"parentId":"CHEMBL513994","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Prx-08066"],"crossReferences":{"drugbank":["DB05607"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL4297409","canonicalSmiles":"COC(=O)c1ccc(-c2ccc(C(=O)OC)cc2)cc1","inchiKey":"BKRIRZXWWALTPU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BIPHENYL DIMETHYL DICARBOXYLATE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Biphenyl dimethyl dicarboxylate","Dimethyl 4,4'-biphenyldicarboxylate","Nissel"],"crossReferences":{"drugbank":["DB12475"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297464","canonicalSmiles":"CS(=O)(=O)c1ccccc1S(=O)(=O)NO","inchiKey":"RZRWBKKAFHXNEQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CXL-1020","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CXL-1020","Cxl-1020"],"crossReferences":{"drugbank":["DB15326"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297487","canonicalSmiles":"CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)CCCCCCNC(C)=O)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)N(C)C1=O","inchiKey":"KBARHGHBFILILC-NGIJKBHDSA-N","drugType":"Protein","blackBoxWarning":false,"name":"CRV-431","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CRV-431","CRV431","Cpi-431","Cpi-431-32","Crv-431","Crv431","Rencofilstat"],"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297734","drugType":"Antibody","blackBoxWarning":false,"name":"CRIZANLIZUMAB","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Adakveo"],"synonyms":["Crizanlizumab","Crizanlizumab-tmca","NVP-LXI-262","NVP-LXI262","SEG-101","SEG101","SEL-G1","SelG1","Selg1"],"crossReferences":{"DailyMed":["crizanlizumab-tmca"]},"linkedTargets":{"rows":["ENSG00000174175"],"count":1},"linkedDiseases":{"rows":["MONDO_0044903","MONDO_0100096","Orphanet_232","HP_0200023","Orphanet_247691"],"count":5},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for sickle cell anemia and has 3 investigational indications."}
{"id":"CHEMBL4297743","drugType":"Antibody","blackBoxWarning":false,"name":"ELEZANUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABT-555","AE12-1Y-QL","Abt-555","Elezanumab","PR-1432051"],"linkedTargets":{"rows":["ENSG00000182175"],"count":1},"linkedDiseases":{"rows":["HP_0002140","MONDO_0005301","EFO_1001919"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297755","drugType":"Unknown","blackBoxWarning":false,"name":"FP-1039","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["FP-1039","Fgf receptor antagonist hgs1036","Fp-1039","GSK-3052230","GSK3052230","Gsk3052230","HGS1036","Hgs-1036"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297800","drugType":"Protein","blackBoxWarning":false,"name":"PEGTEOGRASTIM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Neulapeg","Pegteograstim"],"description":"Protein drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL4297892","drugType":"Unknown","blackBoxWarning":false,"name":"ARX-788","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ARX-788","ARX788","Arx-788","Arx788"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297900","drugType":"Unknown","blackBoxWarning":false,"name":"AZD-4785","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-4785","AZD4785","Azd-4785","Azd4785","ION-651987","ION651987","IONIS-KRAS-2.5RX"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297985","drugType":"Antibody","blackBoxWarning":false,"name":"MAGROLIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hu5F9-G4","Hu5f9 g4","Hu5f9-g4","Magrolimab"],"linkedTargets":{"rows":["ENSG00000196776"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","MONDO_0009348","EFO_0001642","MONDO_0008170","EFO_0000403","EFO_0000222","EFO_0005952","MONDO_0001187","EFO_0000311","EFO_1001951","EFO_0005537","MONDO_0001657","EFO_0008528","EFO_1001051","EFO_0001378","EFO_1000785","EFO_0000181"],"count":18},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."}
{"id":"CHEMBL4298069","drugType":"Enzyme","blackBoxWarning":false,"name":"POLY (ADP-RIBOSE) POLYMERASE 1","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Parp-1","Parp1","Poly (adp-ribose) polymerase 1","Poly(adp-ribose) synthase 1"],"description":"Enzyme drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4303141","canonicalSmiles":"CC(C)C1=C2[C@H]3CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)CC[C@@]2([C@@H](O)CN(CCN(C)C)Cc2ccc(Cl)cc2)CC1=O","inchiKey":"MEOWKUXNVNJAMY-PZFKGGKESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK2838232","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gsk2838232"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL438497","canonicalSmiles":"NC(=O)c1ccc[n+]([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c1","inchiKey":"JLEBZPBDRKPWTD-TURQNECASA-O","drugType":"Small molecule","blackBoxWarning":false,"name":"NICOTINAMIDE RIBOSIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nicotinamide ribonucleoside","Nicotinamide riboside","Ribosylnicotinamide"],"crossReferences":{"drugbank":["DB14933"],"chEBI":["15927"]},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 10 investigational indications."}
{"id":"CHEMBL4462530","canonicalSmiles":"CC(=O)N[C@@H]1CCC[C@H](C(=O)Nc2cc(-c3cnn4c3CC(C)(C)C4)c(Cl)cn2)C1","inchiKey":"AVIWDYSJSPOOAR-LSDHHAIUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-4573","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-4573","AZD4573","Azd-4573","Azd4573"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL458624","canonicalSmiles":"CCCCOc1ccc2cc(S(=O)(=O)N[C@@H](CCC(=O)O)C(=O)O)ccc2c1","inchiKey":"UAGYXJBYAFGRFR-KRWDZBQOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL458624","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08105"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4594272","canonicalSmiles":"Cl.Cl.N#Cc1cccc(C(NCC2CC2)c2ccc(F)c(NC(=O)c3cc(C(F)(F)F)nn3-c3cccc(CN)c3)c2)c1","inchiKey":"XFZLBLTUANGZBD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BEROTRALSTAT HYDROCHLORIDE","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL4594271","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Orladeyo"],"synonyms":["BCX7353.2HCl","Berotralstat dihydrochloride","Berotralstat hydrochloride"],"linkedTargets":{"rows":["ENSG00000164344"],"count":1},"linkedDiseases":{"rows":["Orphanet_91378"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2020 and is indicated for hereditary angioedema."}
{"id":"CHEMBL4594593","drugType":"Unknown","blackBoxWarning":false,"name":"REGN-3051","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["REGN-3051","REGN3051","Regn-3051","Regn3051"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL462170","canonicalSmiles":"O=C(O)CCn1c2ccc(O)cc2c2c3c(c(-c4ccccc4)cc21)C(=O)NC3=O","inchiKey":"JDARUOOLJCFUOY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL462170","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07265"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4650285","canonicalSmiles":"Cn1nccc1Nc1nccc(-c2cc3c(s2)C(C)(C)N(CCN2CCOCC2)C3=O)n1","inchiKey":"JNPRPMBJODOFEC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEMUTERKIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-3214996","LY3214996","Ly3214996","Temuterkib","[14c]-ly3214996"],"childChemblIds":["CHEMBL4802243"],"linkedTargets":{"rows":["ENSG00000102882","ENSG00000100030"],"count":2},"linkedDiseases":{"rows":["EFO_0002618","EFO_0000222","EFO_0000519","EFO_0000311"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4650419","drugType":"Antibody","blackBoxWarning":false,"name":"QUAVONLIMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-1308A COMPONENT QUAVONLIMAB","Quavonlimab"],"linkedTargets":{"rows":["ENSG00000163599"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000756","EFO_0000681","EFO_0000182","EFO_0000702","EFO_0003060","EFO_1001951"],"count":7},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL4650465","drugType":"Unknown","blackBoxWarning":false,"name":"E-7974","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["E 7974","E-7974","E7974","ER-807974"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650511","drugType":"Unknown","blackBoxWarning":false,"name":"RGLS-4326","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RGLS-4326","RGLS4326","Rgls-4326","Rgls4326"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL468419","canonicalSmiles":"Cl.N#Cc1ccc(C2CCCc3cncn32)cc1","inchiKey":"UKCVAQGKEOJTSR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FADROZOLE HYDROCHLORIDE","maximumClinicalTrialPhase":0,"parentId":"CHEMBL9298","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Afema","CGS 16949A","CGS-16949A","Fadrozole hcl","Fadrozole hydrochloride"],"crossReferences":{"PubChem":["144213918"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL481","canonicalSmiles":"CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC","inchiKey":"UWKQSNNFCGGAFS-XIFFEERXSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"IRINOTECAN","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Biotecan","Camptosar","Irinotecan","NSC-728073"],"crossReferences":{"DailyMed":["irinotecan%20hydrochloride"],"PubChem":["124893595"],"Wikipedia":["Irinotecan"],"drugbank":["DB00762"],"chEBI":["80630"]},"childChemblIds":["CHEMBL541887","CHEMBL1200512","CHEMBL3989514"],"linkedTargets":{"rows":["ENSG00000198900"],"count":1},"linkedDiseases":{"rows":["EFO_1000419","EFO_0003891","EFO_0000637","EFO_0000365","EFO_0000681","EFO_0005952","EFO_0000632","EFO_1001951","EFO_0000178","EFO_0000588","MONDO_0002974","MONDO_0021633","MONDO_0008903","EFO_1000251","EFO_1000532","EFO_0002918","EFO_0004288","EFO_1001949","EFO_0002618","MONDO_0002537","EFO_0005922","MONDO_0019465","MONDO_0018271","EFO_1001512","EFO_0005221","MONDO_0008315","MONDO_0001879","EFO_1000026","MONDO_0002691","Orphanet_398934","MONDO_0002165","EFO_1001365","EFO_0003032","EFO_0000574","EFO_1000550","EFO_0007416","MONDO_0021117","EFO_1001465","MONDO_0007254","EFO_0000255","EFO_0001071","MONDO_0044937","MONDO_0020654","MONDO_0001056","MONDO_0002158","EFO_0003968","MONDO_0003165","EFO_0000326","EFO_0002499","EFO_0000183","EFO_0004193","EFO_0000707","EFO_0005588","EFO_0000616","EFO_0003897","EFO_0006859","EFO_0002916","MONDO_0024503","Orphanet_44890","EFO_0000403","EFO_1001042","MONDO_0007576","EFO_0007535","EFO_1001961","MONDO_0005499","EFO_1001471","MONDO_0002120","EFO_0008549","EFO_0002517","EFO_0000702","MONDO_0002367","MONDO_0018906","MONDO_0019004","MONDO_0024880","EFO_0000519","MONDO_0044926","MONDO_0003060","MONDO_0000873","EFO_0003869","MONDO_0016167","EFO_0001075","MONDO_0000956","MONDO_0045056","EFO_1000657","EFO_0000228","EFO_0000565","EFO_0000309","EFO_0006732","EFO_0000389","EFO_0000182","MONDO_0005411","MONDO_0020634","EFO_1000785","EFO_0000364","MONDO_0003000","EFO_0001416","MONDO_0001852","EFO_1000606","EFO_0000197","EFO_1000292","MONDO_0021321","EFO_0000248","MONDO_0008170","EFO_0005842","MONDO_0004669","EFO_0002939","EFO_0000502","EFO_0009708","EFO_1000407","EFO_0001061","MONDO_0044787","MONDO_0000386","EFO_0005537","EFO_1001051","MONDO_0019471","MONDO_0044964","EFO_0002938","MONDO_0100342","MONDO_0015686","MONDO_0004192","MONDO_0044887","MONDO_0003196","EFO_1000475","EFO_1001469","MONDO_0021063","MONDO_0002087","EFO_0000305","MONDO_0001187","EFO_1001480","EFO_1000044","EFO_1000218","EFO_1001013","MONDO_0001475","EFO_0003860","EFO_0006352","MONDO_0001657","EFO_0002617","EFO_1000158","EFO_0000437","EFO_0000503","EFO_0000478","EFO_1000350","EFO_0000313","EFO_0002501","MONDO_0016717","EFO_0004243","MONDO_0021038","EFO_0000621","EFO_0003060","EFO_0000311","EFO_0000095","EFO_0000174","EFO_0004142","MONDO_0003219","EFO_1000895","EFO_0003833","EFO_0000691","MONDO_0021637","MONDO_0001325"],"count":159},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and has 4 approved and 144 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL482505","canonicalSmiles":"CCCCCCC(=O)OC[C@H](COP(=O)(O)O)OC(=O)CCCCCC","inchiKey":"JAXUAGQDLYDLQB-OAHLLOKOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL482505","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08376"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL502620","canonicalSmiles":"CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC","inchiKey":"USZYSDMBJDPRIF-SVEJIMAYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACLARUBICIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aclacinomycin a","Aclarubicin","Aclarubicin hydrochloride","NSC-208734"],"crossReferences":{"drugbank":["DB11617"],"chEBI":["77980"]},"childChemblIds":["CHEMBL1697719"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL503075","canonicalSmiles":"CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O","inchiKey":"FHNIYFZSHCGBPP-ABBMIVAOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"Methyl Beta-D-Lactoside","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Methyl Beta-D-Lactoside"],"crossReferences":{"drugbank":["DB04681"],"chEBI":["610092"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL513","canonicalSmiles":"O=NN(CCCl)C(=O)NCCCl","inchiKey":"DLGOEMSEDOSKAD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CARMUSTINE","yearOfFirstApproval":1977,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bicnu","Gliadel"],"synonyms":["BCNU","Becenun","Bischloroethyl nitrosourea","Camustine","Carmubris","Carmustine","DTI-015","FDA-0345","NSC-409962","SK-27702","SRI-1720"],"crossReferences":{"DailyMed":["carmustine"],"PubChem":["11110902","124879537","144203648","170464880","174007319","26747453","26753530","479311","50105925","57264377","85230955","90341293"],"Wikipedia":["Carmustine"],"drugbank":["DB00262"],"chEBI":["3423"]},"linkedTargets":{"rows":["ENSG00000104687"],"count":1},"linkedDiseases":{"rows":["EFO_0005543","MONDO_0100342","EFO_0007498","EFO_0000756","MONDO_0044887","EFO_1001465","MONDO_0007254","EFO_0002913","EFO_1001469","EFO_0005952","EFO_0000272","EFO_0000305","EFO_1001951","EFO_0000565","EFO_0000096","HP_0001871","MONDO_0003268","EFO_0000389","MONDO_0001657","EFO_0000326","EFO_0002499","EFO_0000183","EFO_0004991","EFO_1000028","EFO_1000785","EFO_1000158","EFO_0000616","MONDO_0008170","EFO_0000403","EFO_1000157","EFO_0002939","EFO_0003929","EFO_0002501","EFO_0002500","EFO_0004599","MONDO_0008315","EFO_0009538","EFO_0000621","EFO_1001383","EFO_0000211","EFO_0000095","EFO_0006475","EFO_0000574","EFO_0004256","EFO_1001051","EFO_0001378","MONDO_0018906","MONDO_0024880","EFO_0003833","EFO_0000519","EFO_0000691"],"count":51},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1977 and has 12 approved and 34 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL514988","canonicalSmiles":"O=C(N/N=C/c1cc(Br)c(O)c(Br)c1O)c1cccnc1","inchiKey":"PYVJEAZDEZTGIS-UBKPWBPPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL514988","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07445"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL52609","canonicalSmiles":"Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O","inchiKey":"IQFYYKKMVGJFEH-XLPZGREQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"THYMIDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2'-deoxythymidine","Deoxyribothymidine","Doxribtimine","NSC-21548","Thymidin","Thymidine","Thymidinedeoxyriboside","Thymine-2-desoxyriboside","Zidovudine related compound d","Zidovudine related compound d rs"],"crossReferences":{"PubChem":["144205113","29215196"],"Wikipedia":["Thymidine"],"drugbank":["DB04485"],"chEBI":["17748"]},"childChemblIds":["CHEMBL2067985"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL541","canonicalSmiles":"O=C(O)c1ccccc1","inchiKey":"WPYMKLBDIGXBTP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENZOIC ACID","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Whitfield's"],"synonyms":["Acidum benzoicum","Benzoate","Benzoic Acid","Benzoic acid","Benzoic acid (e 210)","Benzoicum acidum","Dracylic acid","E-210","E210","FEMA NO. 2131","INS NO.210","INS-210","Menno-florades","NSC-149","Vevovitall"],"crossReferences":{"PubChem":["144209601","144210500","17390022"],"Wikipedia":["Benzoic_acid"],"drugbank":["DB03793"],"chEBI":["30746"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for urinary tract infection."}
{"id":"CHEMBL592","canonicalSmiles":"CN1CC[C@]23CCCC[C@H]2[C@H]1Cc1ccc(O)cc13","inchiKey":"JAQUASYNZVUNQP-USXIJHARSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"LEVORPHANOL","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Aromarone","IDS-NL-007","Levorphan","Levorphanol","RO 1-5431"],"crossReferences":{"DailyMed":["levorphanol%20tartrate"],"Wikipedia":["Levorphanol"],"drugbank":["DB00854"],"chEBI":["6444"]},"childChemblIds":["CHEMBL1628243","CHEMBL2062261","CHEMBL3989768","CHEMBL3249801"],"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0003843"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991 and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL606","canonicalSmiles":"CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC","inchiKey":"OJLOPKGSLYJEMD-URPKTTJQSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MISOPROSTOL","yearOfFirstApproval":1988,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cytotec","Misoprostol","Mysodelle","Topogyne"],"synonyms":["Misoprostol","SC-29333"],"crossReferences":{"DailyMed":["misoprostol"],"PubChem":["11532984","144205563","26755780","26755781"],"Wikipedia":["Misoprostol"],"drugbank":["DB00929"]},"linkedTargets":{"rows":["ENSG00000050628"],"count":1},"linkedDiseases":{"rows":["MONDO_0003061","EFO_0009846","HP_0000132","EFO_0009579","MONDO_0000931","EFO_0002950","HP_0004398","EFO_0003948","HP_0001788","EFO_0000544","MONDO_0004247","EFO_0003917","EFO_1001491","EFO_1000874","EFO_1001255","EFO_0003898","EFO_0004607","EFO_0001073","EFO_0003843","EFO_0000546","MP_0001914","EFO_0009454","EFO_0000731","EFO_1001799","MONDO_0001572","MONDO_0001641","MONDO_0005178","EFO_0000668","EFO_0001062"],"count":29},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and has 7 approved and 16 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL628","canonicalSmiles":"CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O","inchiKey":"BYPFEZZEUUWMEJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENTOXIFYLLINE","yearOfFirstApproval":1984,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Neotren mr","Pentoxifylline","Pentoxil","Trental","Trental 100","Trental 400"],"synonyms":["BL 191","BL-191","C04AD03","NSC-637086","NSC-758481","Oxpentifylline","Oxypentifylline","Pentoxifylline","Pentoxiphyllin"],"crossReferences":{"DailyMed":["pentoxifylline"],"PubChem":["11111613","11111614","124881066","144203774","170465384","26719692","26747196","50085870","50105176","85231180","857899","90341235"],"Wikipedia":["Pentoxifylline"],"drugbank":["DB00806"],"chEBI":["7986"]},"linkedTargets":{"rows":["ENSG00000185527","ENSG00000139053","ENSG00000152270","ENSG00000128271","ENSG00000105650","ENSG00000112541","ENSG00000132915","ENSG00000154678","ENSG00000160191","ENSG00000172572","ENSG00000123360","ENSG00000171408","ENSG00000205268","ENSG00000115252","ENSG00000073417","ENSG00000133256","ENSG00000065989","ENSG00000170425","ENSG00000095464","ENSG00000113448","ENSG00000186642","ENSG00000113231","ENSG00000138735","ENSG00000156973","ENSG00000184588"],"count":25},"linkedDiseases":{"rows":["Orphanet_30391","MONDO_0018373","MONDO_0005090","HP_0001397","EFO_0003869","EFO_1001346","EFO_0000278","EFO_0007444","MONDO_0002009","EFO_0000555","EFO_0001065","EFO_0000401","EFO_0003780","DOID_13406","EFO_1001249","HP_0001643","MONDO_0002462","EFO_1001345","EFO_1001486","EFO_1001821","EFO_0000289","HP_0040187","EFO_0006890","EFO_0003884","EFO_0005046","EFO_0004255","EFO_1000652","EFO_0004272","EFO_0000400","EFO_1000158","EFO_0005761","EFO_0005774","EFO_0000545","EFO_0003928","EFO_0005044","EFO_0000220","EFO_1000844","EFO_0001645","HP_0001919","EFO_0000319","EFO_0001073","EFO_0000384","EFO_0003060","EFO_0000311","HP_0001399","Orphanet_98896","EFO_0000546","EFO_0001422","MONDO_0100096","EFO_0000764","EFO_0004284","MONDO_0005148","EFO_0005672"],"count":53},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1984 and is indicated for cardiovascular disease and has 46 investigational indications."}
{"id":"CHEMBL70971","canonicalSmiles":"COC(=O)Nc1nc2ccccc2[nH]1","inchiKey":"TWFZGCMQGLPBSX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBENDAZIM","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["A 118","BAS-67054F","Bavistin","Carbendazim","Derroprene","EK-578","FB-642","Fenbendazole related compound a","Lignasan","NSC-109874","Thicoper"],"crossReferences":{"PubChem":["144209493","144210796","17389123","26752754","408937","92763967"],"Wikipedia":["Carbendazim"],"drugbank":["DB13009"],"chEBI":["3392"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL748","canonicalSmiles":"C[n+]1ccccc1/C=N/O.[Cl-]","inchiKey":"HIGSLXSBYYMVKI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRALIDOXIME CHLORIDE","yearOfFirstApproval":1964,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1420","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["2-Pam","Contrathion","Duodote","Pralidoxime chloride","Pralidoxime chloride (autoinjector)","Protopam","Protopam chloride"],"synonyms":["2-PAM","2-PAM CHLORIDE","2-PAM Chloride","NSC-164614","Pralidoxime chloride","Protopam"],"crossReferences":{"DailyMed":["pralidoxime%20chloride"],"PubChem":["11533058","144203867","170465059","56422221"],"chEBI":["8355"]},"linkedTargets":{"rows":["ENSG00000087085"],"count":1},"linkedDiseases":{"rows":["EFO_0008546","EFO_0004991"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1964 and is indicated for poisoning and myasthenia gravis."}
{"id":"CHEMBL760","canonicalSmiles":"O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1","inchiKey":"OTBXOEAOVRKTNQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANAGRELIDE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Agrylin","Anagrelide","Xagrid"],"crossReferences":{"DailyMed":["anagrelide%20hydrochloride"],"PubChem":["124892336","26755034"],"Wikipedia":["Anagrelide"],"drugbank":["DB00261"],"chEBI":["142290"]},"childChemblIds":["CHEMBL1200759"],"linkedTargets":{"rows":["ENSG00000152270","ENSG00000172572"],"count":2},"linkedDiseases":{"rows":["EFO_0000616","EFO_0004251","MONDO_0000831","HP_0004419","EFO_0002429","EFO_0000479"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 5 approved and 3 investigational indications."}
{"id":"CHEMBL785","canonicalSmiles":"C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1","inchiKey":"IOVGROKTTNBUGK-SJCJKPOMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RITODRINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ritodrine"],"crossReferences":{"Wikipedia":["Ritodrine"],"drugbank":["DB00867"],"chEBI":["8872"]},"childChemblIds":["CHEMBL1201160"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL87223","canonicalSmiles":"Cc1cc(N)c2cc(NC(=O)Nc3ccc4nc(C)cc(N)c4c3)ccc2n1","inchiKey":"HOUSDILKOJMENG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AMINOQUINURIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aminoquinuride"],"crossReferences":{"PubChem":["104171089","4252577","50107933","50107934"],"drugbank":["DB04452"]},"childChemblIds":["CHEMBL1965412","CHEMBL2132372"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL88611","canonicalSmiles":"Cn1c(=O)c2[nH]c(Cl)nc2n(C)c1=O","inchiKey":"RYIGNEOBDRVTHA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"8-CHLOROTHEOPHYLLINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["8-Chlorotheophylline"],"crossReferences":{"Wikipedia":["8-Chlorotheophylline"],"drugbank":["DB14132"],"chEBI":["59771"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL991","canonicalSmiles":"Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O","inchiKey":"XNKLLVCARDGLGL-JGVFFNPUSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"STAVUDINE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Stavudine","Zerit","Zerit xr"],"synonyms":["BMY-27857","D-4T","D4T","NSC-163661","NSC-759897","Sanilvudine","Stavudine","Stavudine (d4t)","Stavudine (dt4)","Stavudinum","Zerit","d4T"],"crossReferences":{"DailyMed":["stavudine"],"PubChem":["144208591","144210900","170464820","17389053","17389074","26719688","26751536","29215013","49718181","50104116","50104117","56422159","7971664","855856","90341632"],"Wikipedia":["Stavudine"],"drugbank":["DB00649"],"chEBI":["63581"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and has 3 approved and 4 investigational indications. This drug has a black box warning from the FDA."}
